Overall rank by patents
#4,902
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
NGM Biopharmaceuticals, Inc.
USPTO PatentsView assignee record — 71 granted patents across 7 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
71
Total patents granted
7
CPC technology areas
40.5
Avg claims per patent
+15%
5-year filing velocity
Portfolio overview
NGM Biopharmaceuticals, Inc. has been granted 71 US utility patents between 2015 and 2025, placing NGM Biopharmaceuticals, Inc. at rank #4,902 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 40.5 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, NGM Biopharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 43.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 38 grants, compared with 33 in the 2015–2019 window — a +15% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. NGM Biopharmaceuticals, Inc.'s 40.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NGM Biopharmaceuticals, Inc. against peers pursuing similar technology classes.
How does NGM compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- NGM Biopharmaceut… ◀ 71
NGM Biopharmaceuticals, Inc.
71 patents
What this shows NGM holds 71 patents — placing it at rank #4,902 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 4.2% |
| 2016 | 2 | 2.8% |
| 2017 | 8 | 11.3% |
| 2018 | 11 | 15.5% |
| 2019 | 9 | 12.7% |
| 2020 | 10 | 14.1% |
| 2021 | 8 | 11.3% |
| 2022 | 4 | 5.6% |
| 2023 | 10 | 14.1% |
| 2024 | 2 | 2.8% |
| 2025 | 4 | 5.6% |
Which technologies does NGM Biopharmaceuticals, Inc. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing
Frequently Asked Questions
How many patents does NGM Biopharmaceuticals, Inc. hold?
NGM Biopharmaceuticals, Inc. holds 71 US granted patents filed between 2015 and 2025, spanning 7 technology areas.
What is NGM Biopharmaceuticals, Inc.'s Innovation Score?
NGM Biopharmaceuticals, Inc. has an Innovation Score of 43.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does NGM Biopharmaceuticals, Inc. focus on?
NGM Biopharmaceuticals, Inc.'s top technology area is C07K (PEPTIDES) with 68 patents. The company has filed patents in 7 CPC subclasses total.
Is NGM Biopharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
NGM Biopharmaceuticals, Inc.'s recent filing velocity is +15% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for NGM Biopharmaceuticals, Inc.'s patents?
NGM Biopharmaceuticals, Inc.'s patents average 40.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the NGM Biopharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
C07K technology
NGM Biopharmaceuticals, Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where NGM Biopharmaceuticals, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
